Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116)
Authors
Rosen, E.Silverman, I. M.
Fontana, E.
Lee, E. K.
Spigel, D. R.
Hojgaard, M.
Lheureux, S.
Mettu, N. B.
Carneiro, B. A.
Carter, Louise
Plummer, E. R.
Schonhoft, J. D.
Ulanet, D.
Manley, P.
Reis, J. S.
Xu, Y.
Rimkunas, V.
Koehler, M.
Yap, T. A.
Affiliation
Memorial Sloan Kettering Cancer Center, New YorkIssue Date
2022
Metadata
Show full item recordCitation
Rosen E, Silverman IM, Fontana E, Lee EK, Spigel DR, Hojgaard M, et al. Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116). Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680300975.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.3082Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.3082Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.3082